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Abstract 
 
Soren Johnson:  Genetic And Pharmacologic Regulation Of Cyclin 
Dependent Kinase 4 And 6 Activity In Mammalian Hematopoiesis 
(Under the direction of Dr. Norman Sharpless) 
 
Tight regulation of the cell cycle is required to allow necessary cellular 
proliferation while avoiding uncontrolled growth and cancer.  In mammalian 
hematopoiesis, this regulation is particularly important because hematopoietic 
stem and progenitor cells (HSPC) must continuously and rapidly replenish 
circulating blood cells.  Such rapid proliferation leaves HSPC particularly 
susceptible to damage from ionizing radiation (IR), and also increases the risk of 
hematologic malignancies.   Cyclin dependent kinases (CDK) 4 and 6 are 
required for the G1/S-phase transition in HSPC, whereas most other tissues do 
not depend on CDK4/6 activity for cellular proliferation.  Because of this tissue-
specific requirement for CDK4/6 in the hematopoietic system we sought to 
identify the cell cycle effects of selective CDK4/6 inhibitors in cell lines.  Highly 
potent and selective CDK4/6 inhibitors arrested CDK4/6-dependent cells in the 
G1 phase of the cell cycle, while not affecting cells which proliferate 
independently of CDK4/6.  This selective cell cycle arrest successfully protected 
arrested cells from IR, whereas less selective CDK inhibitors did not, and cells 
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that did not require CDK4/6 for proliferation were also not protected from IR.  In 
mice, inhibition of CDK4/6 slowed the proliferation of HSPC, thereby increasing 
murine survival after IR exposure.  Furthermore, therapeutic IR delivered to mice 
with autochthonous melanomas remained an effective anti-tumor treatment when 
the mice received transient CDK4/6 inhibition, though CDK4/6 inhibition did 
improve survival from the IR.  Such pharmacologic manipulation of CDK4/6 
activity would be of use after radiological accidents or as an adjuvant to clinical 
radiotherapy.   
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Chapter 
I.  Introduction: Regulation of the cell cycle by CDK4/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cellular proliferation is a fundamental process in biology.  During each cell 
cycle genetic material must be replicated faithfully, a complex array of proteins 
must be synthesized, and materials must be properly distributed to daughter 
cells.  In eukaryotes, this process of cellular proliferation is regulated by the 
coordinated activity of cyclin dependent kinases (CDKs) and the cyclical 
expression of their catalytic partner proteins, the cyclins.  These cyclin-CDK pairs 
are required to progress cells through each sequential stage of the cell cycle, 
thereby maintaining the ordered progression of the canonical cell cycle.  
Dysregulation of cyclin-CDK activity can lead to uncontrolled cellular proliferation, 
which is one of the “hallmarks of cancer” (1).  Therefore, understanding cyclin-
CDK regulation and their roles in the cell cycle is an important scientific 
steppingstone towards improving human health.   
A. CDK-cyclin pairs driving G1/S-phase traversal 
 Data from bean roots (2), yeast (3, 4), and sea urchins (5) were combined 
to produce the canonical model of the cell cycle: a linear series of cyclin-CDK 
pairs required for progression through the ordered phases (G1ÆSÆG2ÆM; 
reviewed in (6, 7)).  Yeast rely upon one main CDK (Cdc2 in 
Schizosaccharomyces pombe and Cdc28 in Saccharomyces cerevisiae) that 
pairs with different cyclins to achieve target specificity.  In contrast, mammals 
have five main CDKs which drive the cell cycle (CDKs 1, 2, 3, 4, and 6;  
Figure 1), and an additional six CDKs with less well defined roles.  Each CDK 
pairs with one or more of the 16 known cyclins.  In mammals, progression from 
the G1-phase to the S-phase of the cell cycle is primarily driven by CDK4, CDK6, 
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and CDK2, collectively known as the G1 phase CDKs.  CDK4 and CDK6 bind to 
one of the three D-type cyclins (D1, D2, or D3) to phosphorylate the 
retinoblastoma family proteins (Rb, p107, p130), which causes Rb to release E2F 
family transcription factors.  E2F transcription factors initiate transcription of a 
large array of genes associated with S-phase, including cyclins E1, E2, and A2.  
Similarly, CDK2 binds to cyclin E1 or E2, phosphorylates Rb family proteins, 
among other targets, which also leads to release of E2F transcription factors and 
initiation of S-phase. 
 The individual contribution of each of these canonical G1-phase cyclin-
CDK pairs to G1/S-phase traversal has been somewhat controversial (8).  
Although cell cycle dogma originally held that CDK2 was the “master regulator” of 
the G1/S-phase transition (7), individual knockouts of all three of the G1-phase 
CDKs are surprisingly viable and lack severe phenotypes, which clearly reveals 
compensation between CDKs 2, 4, and 6.  While Cdk4 knockout mice possess 
defects only in pituitary lactotrophs and pancreatic beta cells (9, 10), knockouts 
of Cdk6 produce mild defects in erythropoiesis and lymphopoiesis (11), and mice 
lacking Cdk2 demonstrate an inability to complete meiosis due to a block at 
prophase I (12, 13).  These tissue-specific phenotypes reveal subtle 
dependencies for the G1-phase CDKs, but more importantly reveal widespread 
compensation among the G1-phase cyclin-CDKs. 
 Combinatorial knockout experiments of the G1-phase cyclin-CDKs further 
emphasize the redundancy of these kinases in most tissues.  Mice lacking Cdk2 
and Cdk6 have the same phenotypes as the single knockouts, suggesting Cdk4 
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is sufficient in most cells for cellular proliferation (11).  Mice without Cdk2 and 
Cdk4 have a more severe phenotype, dying by postnatal day one due to heart 
defects, though Cdk4-/- animals with ablation of Cdk2 as adults survive normally 
(14).  Knockout of Cdk4 and Cdk6 produces embryos that survive until embryonic 
day 14.5-18.5, demonstrating a nearly complete lack of hematopoiesis (11).  
Surprisingly, the embryos lack defects in most other tissues.  The phenotype is 
mirrored in mice lacking all three D-type cyclins (15), which are the catalytic 
partners to Cdk4 and Cdk6.  Importantly, Cdk2 binds to cyclin D1 and cyclin D2 
in the absence of Cdk4/6 (11), clearly revealing a compensation mechanism that 
allows most tissues in these mice to develop normally. 
 Even more surprising evidence of the promiscuity of cyclin-CDK pairs is 
observed by the survival of embryos lacking all three of the G1-phase CDKs to 
embryonic day 13.5-15.5 (16).  Embryos lacking Cdk2, Cdk4, and Cdk6 die due 
to hematopoietic and heart defects, whereas other tissues develop normally, 
although the embryos are undersized.  These data reveal that Cdk1 can 
compensate for the loss of all three of the G1-phase Cdks during early 
embryogenesis, and that cyclin-CDK pairings are highly promiscuous; Cdk1-
cyclin D and Cdk1-cyclin E binding can successfully drive forward the G1/S-
phase transition, even though in wildtype cells Cdk1 binds to cyclin B and rarely 
binds cyclin D or E.  From these data Malumbres and Barbacid have proposed a 
model of the mammalian cell cycle whereby CDK1 is the only essential kinase 
and may pair with any of the cyclins, mirroring the simpler yeast cell cycle (Figure 
1) (17)).  Layered on top of this fundamental reliance on CDK1, the other CDKs 
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are important for more specialized roles such as the G1/S-phase transition, but 
are only absolutely required for cellular proliferation in specific cell types. 
While expression varies somewhat by cell type, CDK expression during 
each cell cycle is relatively constant (18).  Cyclin expression, however, depends 
mostly upon timing of the cell cycle (5).  Cyclins are quickly degraded when the 
cell cycle progresses (19-21).  Additional determinants of cyclin expression 
include cell type, developmental timing, and mitogen stimulation (22-27).   
B.  Cell cycle inhibitors during the G1/S-phase transition 
Cell cycle regulation is further complicated by the role of CDK inhibitor 
proteins, which act primarily to inhibit active cyclin-CDK complexes from 
phosphorylating their targets by allosteric changes upon binding (28, 29).  
Specifically regulating the G1/S-phase transition, the CIP/KIP family of CDK 
inhibitors (which includes p21CIP1/WAF1, p27KIP1, and p57KIP2) predominantly 
inhibits CDK2, whereas the inhibitors of CDK4 (INK4 proteins p16INK4a, p15INK4b, 
p18INK4c, and p19INK4d) prevent cyclinD-CDK4/6 activity (reviewed in (30)).  The 
ability of the these cell cycle inhibitors to partner with non-canonical CDKs and 
prevent their kinase activity has been controversial (7, 31-35), though the 
majority of evidence suggests p21 and p27 can promiscuously inhibit all the G1-
phase CDKs, while the INK4 proteins have a more restricted role in inhibiting 
primarily CDK4/6 (36). 
C.  The cell cycle and hematopoiesis 
As the Cdk4/6 (11) and cyclin D (15) knockouts revealed, early murine 
hematopoiesis has a specific requirement for Cdk4/6-cyclin D activity.  Murine 
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and human hematopoiesis has been carefully studied, revealing a well-defined 
hierarchy of cell division (Figure 2), with each stage of hematopoietic 
development identifiable through a combination of cell surface antigens.  At the 
top of this hierarchy is the hematopoietic stem cell (HSC), a population of cells 
which rarely divides; estimates range from one cell division every few days (37) 
to once every two weeks (38).  The HSC divides asymmetrically to both self-
renew and produce a multipotent progenitor (MPP), which proliferates 
substantially more rapidly (cycling once every 1-2 days (37)).  Like the HSC, the 
MPP is able to differentiate into any hematopoietic cell type, but cannot 
reconstitute a transplanted animal long term because it lacks the ability to self-
renew (39, 40).  After some expansion in cell number, the MPP eventually 
differentiates into one of several oligopotent progenitor cell types which have 
restricted differentiation potential:  the common myeloid progenitor (CMP), the 
common lymphoid progenitor (CLP), the granulocyte-monocyte progenitor 
(GMP), or the megakaryocyte-erythroid progenitor (MEP).  Although the exact 
hierarchy and trans-differentiation potential of these oligopotent progenitors is 
debated, it is widely accepted that under most circumstances these differentiation 
categories are fairly rigid (i.e., the MEP can only give rise to megakaryocytes and 
erythroid cells, not lymphocytes; noted exceptions in (41, 42)).  Collectively, 
these hematopoietic stem and progenitor cells (HSPC) must produce roughly 
1011 fully differentiated cells of nine different cell types every day in humans, and 
the HSC has such massive proliferative potential that a single cell can 
reconstitute the entire hematopoietic system of a mouse (43). 
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Interestingly, detailed examination of cell cycle protein expression in mice 
has revealed subtle difference in the cell cycle machinery at each stage of 
hematopoiesis (37).  These data are important because accumulating evidence 
suggests that mechanisms of quiescence regulate HSPC ability to self-renew 
and proliferate.  Notably, CDK inhibitor p18INK4c seems to limit HSC self-renewal 
(44), while p21CIP1 (45-47) and p16INK4a (48) are important for maintaining HSC 
quiescence.  Early hematopoietic progenitors, but not HSC, are limited by p27KIP1 
expression (49).  The importance of these CDK inhibitors in HSPC biology 
certainly suggests that their targets, the G1-phase CDKs, are key to determining 
HSPC function.  As such, identifying the precise cell cycle events that lead to 
proliferation in HSPC is critical to maximizing recovery from any type of 
hematopoietic insult, such as IR exposure or chemotherapy. 
D. Summary: CDK4/6 regulation of the cell cycle 
 CDK-cyclin pairs drive progression through the cell cycle, and their 
dysregulation often underlies cancer.  High degrees of redundancy, the large 
number of cyclin-CDK pairs, and diversity of targets adds enormous complexity 
to cell cycle regulation, but understanding each cyclin-CDK pair’s function 
reveals tissue-specific CDK requirements that may be leveraged for therapeutic 
benefit.  In particular, while most mammalian cells can proliferate in the absence 
of CDK4/6 activity, HSPC absolutely require CDK4/6-cyclinD for cellular 
proliferation.   
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Figure 1:  The mammalian cell cycle.  (A) The essential cell cycle:  CDK1 is 
the central kinase able to sustain cellular proliferation in most cells in the 
absence of CDKs 2, 4, and 6.  (B) The specialized cell cycle: Each of the CDKs 
have specialized roles for cell cycle progression, essential only in specific 
tissues.  [Adapted from (17).] 
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Figure 2:  Hierarchy of mammalian hematopoiesis.  Murine cell surface 
antigens used to detect specific HSPC populations are listed. [Modified from (50) 
with permission.] 
19 
 
 
 
 
 
Chapter 
 II. Ionizing radiation and the cell cycle 
 
 
 
 
 Originally identified by Roentgen in 1895, the medical imaging applications 
of X-rays were immediately recognized, as was the potential for the X-ray as an 
anti-tumor treatment.  Many advances in external beam radiation therapy 
methods have improved clinical outcomes over the subsequent 115 years, but 
clinical radiation therapy has largely failed to capitalize upon findings that IR is 
not uniformly lethal throughout the cell cycle.  The work presented here aims to 
make use of cell cycle dependent IR in order to improve clinical outcomes during 
therapeutic IR as well as to improve treatment from radiological accidents. 
A.  Mechanisms of IR cytotoxicity 
On a molecular scale, IR is analogous to a widespread ballistic injury, 
though with the added complexity of wave energy and secondary ionization 
events.  The subcellular mechanisms of injury and injury response can be highly 
heterogeneous, even from a single type of IR.  But a general overview of IR 
mechanisms and the cellular response aid an understanding of how cell cycle 
regulation can modulate IR toxicity. 
Physics of IR (reviewed in (51, 52)) – In external beam radiation, 
commonly used for clinical radiotherapy, the primary source of IR is X-rays.  X-
rays are high energy, short wavelength photons produced by the high speed 
collision of electrons with a metal plate in a vacuum.  Although less commonly 
used in the clinic, the natural nuclear decay of 137Cs or 60Co produces gamma 
rays (γ-rays), which are photons with similar energies to X-rays.  Radiological 
explosions from nuclear devices or exposure to other radioactive isotopes could 
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produce a wide variety of photon types or particulate IR which would have 
different biological consequences from the more widely studied X- and γ-rays. 
IR damage is caused by both the direct disruption of hydrogen and 
covalent bonds by a high energy particle, as well as by secondary events caused 
by the formation free radicals.  Direct damage is greater with particulate forms of 
IR, and less important in photon-based IR such as X-rays and γ-rays.  Instead, 
the majority of the damage caused by X- and γ-rays is due to formation of 
reactive oxygen species (ROS), especially the formation of hydroxyl radicals from 
water (53, 54), which can cause secondary lesions by rapid oxidation of proteins, 
DNA, or lipids within a cell. 
For long term survival after IR, particularly in the context of stem cells, 
damage to DNA is considered the most lethal; unrepaired mutations produced by 
IR will be propagated in daughter cells, if a cell retains proliferative potential at 
all.  Nucleotide base damage is the most common DNA lesion caused by IR, 
occurring at least 2.5 times per single strand break (SSB) (55, 56), though simple 
base damage is the easiest form of DNA damage for a cell to reliably repair.  
Approximately 300-1000 SSB/cell form after 1 Gy of IR (54, 56).  The same dose 
causes 150 DNA-protein crosslinks (57), and 40 double strand breaks (DSB), 
which are both much more likely to be lethal cellular events (52).  Interstrand 
crosslinks (ICLs) may be even more lethal than DSBs, though their frequency 
after IR and their lethality are not well characterized (58, 59). 
Cellular response to IR — After IR induced DNA damage the cell rapidly 
initiates DNA damage response (DDR) mechanisms and signaling.  Although the 
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precise mechanisms depend on the exact type of DNA damage, in general 
damage is sensed by RAD17-RFC or the 9-1-1 complex (reviewed in (60)).  
These complexes activate ATM, ATR, or DNA PK, each of which may also have 
some role in sensing damage as well as signal transduction (61).  In the case of 
IR, evidence suggests ATM is of primary importance (62).  ATM activates CHK2, 
a serine/threonine kinase that phosphorylates a wide variety of substrates to 
effect the ultimate cellular outcome: repair, senescence, or cell death.  In most 
mammalian cells, IR causes a robust ATM- CHK2- and p53-dependent 
upregulation of p21CIP1, which arrests cells by inhibiting CDK2 as well as CDK4/6 
(reviewed in (63)).  Though this pathway is robust and present in most cell types, 
ATM-CHK2 activation after IR has numerous consequences in addition to p53-
dependent responses (reviewed in (64)).  Notably, DNA damage signaling 
through either ATM or ATR activates CHK2 or CHK1, respectively.  Both CHK2 
and CHK1 inhibit Cdc25, a kinase that aids activation of CDK2/4/6. 
B. Cell cycle dependence of IR cytotoxicity 
At least as early as 1929, IR was noted to delay cell division (65), but a 
more detailed understanding of IR and cell cycle did not emerge until the 1960s 
(66).  Across a wide variety of metazoan cell types, cells exhibit relative 
radioresistance during early G1-phase and late S-phase, and show relative 
radiosensitivity near the G1/S-phase transition, at the G2/M-phase transition, and 
during mitosis (62, 67, 68).   Radiosensitivity during the cell cycle correlates 
strongly with the timing of key cell cycle checkpoints (69), which suggests an 
important role for cell cycle inhibitors and cell cycle arrest in surviving IR 
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exposure.  Indeed, experimental evidence supports the theory that cell cycle 
checkpoints enable cells to repair DNA damage prior to entry into S-phase or M-
phase (70-72). 
Mechanistically, radiosensitivity prior to DNA replication or prior to mitosis 
makes sense based simply on DNA metabolism.  Traversing G1/S-phase while 
DNA lesions exist is highly genotoxic because the lesions will be propagated or 
converted to more toxic lesions during DNA replication (73).  SSBs and ICLs stall 
replication forks if they are not repaired prior to DNA replication during the S-
phase.  Stalled replication forks often result in collapse of the DNA replication 
fork complex, and are then often converted to DSBs due to the action of single 
strand nucleases (74).  In contrast to the genotoxicity of G1/S-phase traversal, 
traversing G2/M-phase while harboring DNA lesions is often cytotoxic, as any 
DSB could trigger chromosomal rearrangements or mitotic catastrophe if 
chromosomes misalign or mis-segregate during metaphase (75). 
Cyclin-CDK activity has been found to affect cellular survival from IR 
independently of the mechanics of DNA replication and segregation.  Total CDK 
levels affect DNA repair (76).  CDK2 phosphorylates BRCA1 (77) and CtIP (78), 
both critical proteins for DSB repair.  The G1-phase also seems to have higher 
rates of DNA repair compared to other stages of the cell cycle (79), though G1 
cyclin-CDK activity has not been unequivocally linked to rates of a specific DNA 
repair mechanism.  Also, evidence suggests there is a lower threshold for DNA 
damage to engage cell death pathways in late G1 or early S-phase, likely as a 
result of E2F activation (80).  Therefore, affording more time for DNA repair by 
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limiting G1/S traversal is protective by virtue of avoiding hypersensitive activation 
of cell death. 
DNA topography may also have a small role in cell cycle dependent 
radiosensitivity.  Cells in G1 may be more radioresistant than cells in G2 simply 
because there is more DNA susceptible to free radical damage after DNA 
replication (81).  Conceptually, if a 4N cell contains twice as much DNA it will 
sustain more DNA damage than a 2N cell under the same conditions.  However, 
DSB often arise due to multiple DNA lesions occurring in close proximity on 
opposite strands of DNA, and therefore the density of damage plays some role in 
determining the lethality of IR.  The chromatin state may also be an important 
factor in both the quantity of DNA damage and in the efficacy of repair.  Actively 
transcribed genes are repaired more rapidly than heterochromatic regions (82), 
possibly due to differences in the ability of the DDR complexes to access the 
damage.  Furthermore, there are overlapping roles for heterochromatin proteins 
in both chromatin organization and DDR (83, 84).     
C. Summary: IR and cell cycle 
IR produces potentially lethal DNA lesions primarily through ROS causing 
DSBs.  Changes in the sensitivity of cells to IR during the cell cycle may reflect 
alterations in DNA topography or changes in the DDR.  These somewhat subtle 
alterations in radiosensitivity, when combined with the tissue-specific requirement 
for CDK4/6 in HSPC, provide an opportunity to improve the radioresistance of 
mammalian HSPC after IR. 
 
 
 
 
 
Chapter 
 III. Pharmacologic inhibition of CDK4/6 for radiomitigation in mice1 
 
 
 
 
 
 
 
 
 
 
 
                                                 
1 This chapter will be published in the Journal of Clinical Investigation in July of 2010, 
and is reproduced with permission from the American Society for Clinical Investigation. 
 
 
 
A.  Abstract 
Total body irradiation (TBI) can induce lethal myelosuppression, reflecting 
the sensitivity of proliferating hematopoietic stem/progenitor cells (HSPC) to 
ionizing radiation (IR).  No effective therapy exists to mitigate the hematologic 
toxicities of TBI.   Here, using selective and structurally distinct small molecule 
inhibitors of cyclin dependent kinases 4 and 6 (CDK4/6), we demonstrate in vivo 
radioresistance associated with cellular quiescence.  In vitro, cell lines dependent 
on CDK4/6 were resistant to IR and other DNA damaging agents.  In contrast, 
CDK4/6 inhibitors did not protect cell lines that proliferated independently of 
CDK4/6 activity, and non-selective CDK inhibitors did not afford protection.  In 
vivo, treatment of wild-type mice with CDK4/6 inhibitors induced reversible 
pharmacologic quiescence (PQ) of early HSPC, but not most other cycling cells 
in the bone marrow or other tissues.  Selective PQ of HSPC decreased the 
hematopoietic toxicity of TBI, even when CDK4/6 inhibitor was administered 
several hours after TBI.  Moreover, PQ at the time of administration of 
therapeutic IR to mice harboring autochthonous cancers reduced treatment 
toxicity without compromising the therapeutic tumor response  These results 
demonstrate an effective method to mitigate the hematopoietic toxicity of IR in 
mammals, potentially useful after radiological disaster or as an adjuvant to anti-
cancer therapy.   
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B.  Introduction  
 The cytotoxicity of DNA damaging agents such as IR is cell cycle 
dependent.  In particular, early G1 and late S phases are relatively radioresistant, 
whereas the G1/S transition and G2/M phases are relatively radiosensitive (66, 
67).  Traversing from G1 to S phase while harboring DNA damage is particularly 
genotoxic (80), and an extended period of G1 after exposure to genotoxins 
enhances resistance (85-87), possibly by allowing for greater DNA repair prior to 
G1/S traversal.  We therefore reasoned that modulating the cell cycle by 
lengthening G1 may mitigate the toxicity of DNA damaging agents such as IR.  
The transition from G1 to S phase is regulated by at least three CDKs 
(CDK 2/4/6) and their catalytic partner cyclins (cyclin A/D/E) functioning in 
concert to phosphorylate the Rb-family proteins (reviewed in (6)).  Combinations 
of CDK-cyclin gene knockouts in mice have revealed considerable redundancy 
and/or developmental compensation among these proteins (reviewed in (8)).  For 
example, murine embryos lacking both CDK4 and CDK6 or all the D-type cyclins 
demonstrate normal proliferation in many tissues, but succumb late in 
development due to a lack of fetal hematopoietic stem and progenitor cells (11, 
15).  Likewise, in adult mice, pharmacologic inhibition of CDK4/6 activity is well-
tolerated, only inhibiting proliferation in a few, CDK4/6-dependent cell types (88).  
Importantly, CDK2 and CDK1 phosphorylate several non-Rb substrates that 
regulate additional processes such as transcription and DNA metabolism 
(reviewed in (89)), whereas CDK4/6 are highly specific to Rb-family proteins.  
Based on these observations, we hypothesized that we could improve resistance 
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to DNA damaging agents by inducing a G1-arrest using selective pharmacologic 
CDK4/6 inhibitors.     
C.  Results  
To test this hypothesis in vitro, we first screened putative CDK4/6 
inhibitors for their cell cycle effects in several human cell lines.  CDK4/6 
dependent cell lines, including telomerized human diploid fibroblasts (tHDF) and 
a human melanoma cell line, WM2664, demonstrated strong, reversible G1-
arrest (pharmacological quiescence, PQ) after exposure to the potent and 
selective CDK4/6 inhibitors PD0332991 (90, 91) or 2BrIC (92), whereas the less 
selective CDK inhibitors that additionally target CDK1/2 (roscovitine (93), R547 
(94), and flavopiridol (95)) variably produced a G2/M block, intra-S arrest, or cell 
death in these cell types (Figure 3-Figure 4 and data not shown).  Effects of the 
non-selective CDK inhibitors were similar on an Rb-null melanoma line A2058, 
whereas the selective CDK4/6 inhibitors had no effect on A2058 cell cycle or 
survival, even at doses well above the IC50 in CDK4/6-dependent cell lines 
(Figure 3-Figure 4).  The proliferation of seven Rb-deficient human small cell lung 
cancer lines was also resistant to CDK4/6 inhibitors (not shown), again 
reinforcing the notion that Rb-null cells are generally unaffected by CDK4/6 
inhibition.  These data show that structurally distinct, potent and selective 
CDK4/6 inhibitors effect a “clean” G1-arrest in susceptible cell lines, whereas the 
cell cycle effects of more global CDK inhibitors are less predictable and 
associated with cytotoxicity. 
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Having identified two highly selective CDK4/6 inhibitors that elicit a clean 
G1 arrest in dependent cells, we next sought to determine if PQ was protective 
from cell-cycle dependent genotoxic events in CDK4/6-dependent cell lines.  IR 
exposure (Figure 5) and doxorubicin exposure (Figure 6) both caused extensive 
DNA damage (phospho-γH2AX foci and DNA strand breaks), elicited a robust 
DNA damage response (phospho-p53 and p21CIP/WAF expression), and caused 
cell death (WST-1 assay) in all three cell lines. Treatment with PD0332991 or 
2BrIC prior to genotoxic stress attenuated γH2AX formation (Figure 5-Figure 7), 
DNA strand breaks (Figure 5Figure 7), DNA damage response (Figure 5Figure 
6), and promoted cellular survival in CDK4/6-dependent cell lines WM2664 and 
tHDF (Figure 6-8). Similar protection was observed after exposure to another 
DNA damaging agent, etoposide (not shown).  In contrast, no protective effects 
of PD0332991 or 2BrIC were noted in Rb-deficient A2058 cells (Figure 6Figure 
8), and the less selective CDK inhibitors (roscovitine, flavopiridol, and R547) 
failed to enhance cell survival in any cell line (Figure 8).  The failure of the less 
selective inhibitors to afford protective PQ suggests that arrest in a phase of the 
cell cycle other than G1 (e.g. G2/M) may not protect from genotoxic exposure.  
Alternatively, the less selective CDK inhibitors may prevent phosphorylation of 
non-Rb family substrates by CDK2 (e.g., BRCA1 (96) or CtIP (78)) and thereby 
untowardly augment the toxicity of DNA damaging agents.  Together, these data 
show that PQ effected by selective CDK4/6 inhibitors, but not more global CDK 
inhibitors, provides in vitro resistance to DNA damaging agents in cell types that 
require CDK4/6 kinase activity for G1 to S traversal. 
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To further test whether the protective effects of selective CDK4/6 inhibitors 
required the induction of G1 arrest, we performed cell synchronization 
experiments. CDK4/6-dependent cells were released from CDK4/6 inhibition and 
allowed to progress to G2/M prior during doxorubicin exposure (schematic Figure 
6).  Under such conditions, tHDF and WM2664 demonstrated a marked increase 
in cellular toxicity as measured by increased γH2AX foci, increased DNA damage 
response, and decreased cellular survival (Figure 6).  Therefore, cells benefit 
from CDK4/6 inhibition only when it results in a G1 arrest, and cells in G2 have 
enhanced sensitivity to DNA damage.  This conclusion is supported by the 
observation that other means of promoting a G1-arrest (e.g. staurosporine 
treatment in certain cell types (97)) can also enhance protection from genotoxic 
agents.   
These in vitro data suggest that CDK4/6-depependent tissues in vivo 
might also be protected from DNA damaging agents by CDK4/6 inhibitors.  
Motivated by prior work showing that fetal hematopoietic progenitors require 
CDK4/6-cyclinD for proliferation (11, 98) as well as the clinical need to protect the 
hematopoietic system from DNA damaging agents,  we sought to determine 
whether hematopoietic progenitors could be rendered pharmacologically 
quiescent in vivo.  Proliferation of murine hematopoietic stem cells (HSC; Lin-
Kit+Sca1+CD48-CD150+) as measured by Ki67 expression and incorporation of 
bromodeoxyuridine (BrdU) over 24 hours (Figure 9), was comparable to prior 
estimates (37, 99).  When PD0332991, which is orally bioavailable, was 
administered for 48 hours prior to bone marrow harvest, the frequency of HSC 
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proliferation significantly decreased (Figure 9), with the greatest effect observed 
in Ki67 expression.  An even more pronounced inhibition of proliferation was 
noted in the more rapidly proliferating multipotent progenitor cell compartment 
(MPP; Lin-Kit+Sca1+CD48-CD150-).  Oligopotent progenitors (Lin-Kit+Sca1-) 
demonstrated a modest inhibition of proliferation, with the strongest effects seen 
in common myeloid progenitors (CMP) and common lymphocyte progenitors 
(CLP) compared to weaker effects in the more differentiated granulocyte-
monocyte progenitors (GMP) and megakaryocyte-erythroid progenitors (MEP; 
Figure 9).  In contrast to these effects on early HSPC, no change in proliferation 
was noted in the more fully differentiated Lin-Kit-Sca1- and Lin+ cells, though 
these fractions are heterogeneous and effects on subpopulations may be 
obscured.   
These effects on immunophenotypic HSPC frequency were validated by 
other methods.  Transient (48 hour) treatment with PD0332991 did not decrease 
total marrow cellularity (Figure 10), but did decrease the absolute number of 
lineage negative cells (Figure 9) without altering HSPC apoptosis or viability 
(Figure 10).  The frequency of the more abundant oligopotent progenitors 
declined (Lin-cKit+Sca1-; Figure 9Figure 10), with an associated relative increase 
in HSC and MPP frequencies.  Cobblestone area forming cell assays confirmed 
that transient CDK4/6 inhibition did not decrease in vivo HSPC number (Figure 
10).    In combination, these data suggest a gradient of dependence on CDK4/6 
activity for proliferation during myeloid/erythroid differentiation: the least 
differentiated cells (HSC, MPP and CMP) appear to be the most dependent, with 
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more differentiated elements (GMP and MEP) being less dependent, and even 
more differentiated myeloid and erythroid cells proliferating independently of 
CDK4/6 activity.   
In accord with this model, serial daily treatment with PD0332991 for 12 
days caused a modest decrease in the erythroid, platelet and myeloid (monocyte 
+ granulocyte) lineages which only became apparent after 8 days of treatment, 
and which began to improve within 4 days upon cessation of PD0332991 (Figure 
11). These observations are consistent with the kinetics and degree of 
myelosuppression seen when tumor bearing mice (88) or human patients with 
malignancies (100, 101) are serially treated with PD0332991. These data confirm 
that the short-term production of differentiated peripheral blood effector cells is 
relatively resistant to CDK4/6 inhibition, and that the myelosuppressive effects of 
CDK4/6 inhibition are rapidly reversible in vivo. 
Given that PQ affords cellular protection in vitro (Figure 5Figure 6) and 
effects a specific G1-arrest of HSPC in vivo (Figure 9), we next sought to test 
whether CDK4/6 inhibition would render wild-type mice resistant to the 
hematological toxicity of TBI administered at doses around the LD90 (7.5 Gy).  
Adult female C57Bl/6 mice were exposed to 6.5, 7.5, or 8.5 Gy with or without 
PD0332991 treatment (administered as in Figure 12) and followed for 40 days 
post-TBI.  Marked protection from the hematological toxicity of peri-lethal doses 
of TBI was observed: nearly all untreated mice succumbed to death from 
hematological toxicity when exposed to 7.5 Gy, whereas all treated mice survived 
(Figure 12).  At 8.5 Gy TBI, PD0332991 treatment significantly increased the 30 
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day survival (13% vs. 0%) and prolonged the median survival (19 days vs. 13 
days, Figure 13).  All mice survived after a dose of 6.5 Gy regardless of 
PD0332991 treatment (Figure 13).  These data show that PQ resulting from 
transient CDK4/6 inhibition around the time of TBI enhances radioresistance in 
vivo.  
Because three doses of PD0332991 at different times relative to TBI 
provided radioprotection, we next sought to determine which of these doses was 
most important for radioprotection.  We observed that most of the benefit of the 
treatment schedule was associated CDK4/6 inhibitor treatment immediately prior 
to or contemporaneous with TBI at the LD90.  Mice treated with a single -4 hour 
dose or a single time 0 dose demonstrated survival similar to animals treated on 
the multi-dose (-28, -4, +20) schedule (Figure 12).  This -4 hour benefit was 
confirmed in a larger cohort of mice (N=62), including matched animals from 
three different inbred strains (C57Bl/6, C3H and FVB/n) and both male and 
female mice (Figure 12).  Surprisingly, even a single dose 20 hours after TBI 
significantly enhanced survival after TBI (Figure 12).  As therapeutic serum levels 
are not achieved until >30 minutes after gavage and then persist for 10-20 hours 
(not shown), these observations suggest that a period of PQ lasting for several 
(>20) hours after the induction of DNA damage is beneficial.  Although there are 
a few known compounds that protect from radiotoxicity when administered prior 
to IR (i.e. “radioprotectants”) (102, 103), we are unaware of any hematological 
“radiomitigants”; that is, compounds that reduce myelotoxicity when administered 
many hours after an exposure to TBI.   
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TBI at doses employed in this study causes morbid pancytopenia, with 
count nadirs occurring 14-21 days post-TBI (104).  To confirm that the improved 
survival afforded by PQ was due to protection of hematopoietic lineages, we 
examined the bone marrow and peripheral blood of animals after IR exposure.  
We observed a marked reduction of caspase activity in bone marrow 
mononuclear cells harvested 16 hours post-TBI from mice that had been pre-
treated with PD0332991 prior to TBI (Figure 12).  In accord with this protection 
observed in the bone marrow post-TBI, we also observed that PD0332991 
treatment significantly ameliorated pancytopenia in lethally irradiated mice 
(Figure 12).  A similar improvement of cell count nadirs and more rapid cell count 
recovery was observed after a sub-lethal dose of TBI (Figure 14). Importantly, 
PQ-therapy had a beneficial effect on the recovery of all peripheral blood 
lineages: platelets, erythrocytes, myeloid cells (granulocytes + monocytes), and 
peripheral lymphocytes.  The improvement in quadrilineage hematopoiesis after 
TBI is consistent with the notion that CDK4/6 inhibition exerts maximal 
radioprotection in the early HSPCs rendered quiescent by CDK4/6 inhibitor 
treatment. 
In order to bolster these pharmacologic data, we next turned to a genetic 
model.  Prior work in mice has shown that p21CIP, a potent CDK inhibitor and 
critical mediator of the p53-mediated DNA damage response (105, 106), plays an 
important role in regulating HSPC quiescence after DNA damage (46).  To test 
the importance of p21CIP in hematologic radiomitigation, we exposed inbred 
p21CIP null, heterozygous, and wild-type littermates to lethal TBI both with and 
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without (Figure 15) PD0332991.  For these experiments, an x-ray IR source was 
used at a dose greater than the LD90. Confirming the critical role of p21CIP in 
mediating cellular survival after IR, survival post-TBI strongly correlated with 
p21CIP gene dosage: p21CIP null animals were most sensitive, while wild-type 
animals were most resistant, and heterozygotes were intermediate (Figure 15).  
Administration of PD0332991 four hours prior to TBI improved survival in all three 
genotypes, but PD0332991 treatment did not fully rescue the radiosensitivity of 
p21CIP null mice (Figure 15).  These observations are in accord with PQ data 
(Figure 12) suggesting that the induction of a cell cycle pause well after the onset 
of DNA damage improves HSPC survival.  Moreover, the beneficial effects of PQ 
post-TBI do not strictly require p21CIP, although expression of this CDK inhibitor 
appears to enhance the effects of PQ. 
Prior work has suggested that some radioprotectant strategies are 
associated with an increased late risk of leukemia (107), presumably resulting 
from an augmented survival of damaged cells post-IR.  To assess the risk of late 
toxicity, we serially examined mice after TBI in the presence or absence of PQ.  
When followed 210-274 days post-TBI, no deaths were seen in any animals after 
6.5 Gy TBI regardless of PD0332991 treatment. Only two of 18 mice (one C3H 
and one C57Bl/6) survived 7.5 Gy TBI in the absence of PQ, and these animals 
showed no evidence of disease 143 to 252 days post-TBI.  Of 29 mice surviving 
the acute toxicity of 7.5 Gy TBI in the setting of PQ, there was one death of 
unknown cause at day 99 post-TBI, with the remaining mice disease free 101-
251 days post-TBI.  Blood counts on long-term surviving animals were 
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comparable among unirradiated and irradiated mice, with or without PD0332991 
treatment at the time of TBI (Figure 16).  No evidence of myeloproliferative 
disorder or myelodysplasia was seen in animals of these long-term surviving 
cohorts. These data indicate that PQ does not exacerbate the late hematological 
toxicity associated with sub-lethal TBI, and affords good long-term hematological 
radioprotection even after a lethal dose of TBI. 
Although these results demonstrate the ability of PQ to reduce the toxicity 
of DNA damaging agents, exposure to IR and other DNA damaging agents more 
commonly occurs therapeutically in the treatment of cancer.  To determine if PQ 
could protect the bone marrow of a tumor-bearing host without also protecting its 
cancer, we examined the effects of PQ on tumor response in a well-defined, 
genetically engineered murine model (GEMM) of melanoma (108).  In this model, 
male TyrRas p16INK4a/Arf-/- mice develop autochthonous melanomas, driven by 
melanocyte-specific expression of mutant H-Ras in the setting of combined 
p16INK4a and Arf inactivation (Figure 17).  Even though development of these 
tumors is facilitated by loss of p16INK4a (109), a potent CDK4/6 inhibitor, their 
growth was not inhibited by serial CDK4/6 inhibitor treatment (Figure 17), 
suggesting established tumors in this model do not require CDK4/6 activity for 
continued proliferation.  Moreover, these tumors are sensitive to IR, with 7.5 Gy 
of TBI arresting tumor growth for ~20 days post-IR, whereas all unirradiated 
tumors demonstrated overt progression within 10 days (Figure 17).  When tumor-
bearing mice were treated with a single dose of PD0332991 four hours prior to 
TBI, however, an impressive rescue of radiation-induced morbidity in terms of 
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weight loss (Figure 18) and mortality (Figure 17) was seen without a change in 
tumor response (Figure 17).  These data reveal that PQ can reduce treatment-
associated myelosuppression after exposure to DNA damaging agents without 
concomitantly protecting an established, CDK4/6-independent cancer.   
D.  Discussion  
The cell cycle phase has long been linked to cellular radiosensitivity (66, 
67), and attempts to modify radiosensitivity through manipulation of the cell cycle 
were originally described several decades ago (110, 111).  The approach 
described in the present work adds specificity for HSPC through selective 
pharmacologic inhibition of CDK4/6.  Our data demonstrate such inhibition 
induces a G1 arrest in CDK4/6-dependent cells (Figure 3), thereby protecting 
such cells from genotoxins.  In contrast, cells that do not require CDK4/6 activity 
for proliferation are not arrested by CDK4/6 inhibitors and are not protected by 
such agents (Figure 5Figure 6).  Likewise, less selective CDK inhibitors that 
target CDK1/2 among other kinases do not induce a clean G1 arrest in vitro, and 
do not afford protection from DNA damaging agents.  If anything, in our studies, 
non-selective CDK inhibitors appear to augment the toxicity of DNA damaging 
agents, in accord with prior work from several other groups (78, 112, 113). 
Although the precise mechanism(s) by which an augmented G1 arrest 
protects cells from IR cytotoxicity are not well understood, our data support a few 
possible explanations.  We show that cells arrested in G1 demonstrate an 
increased resistance to the DNA damaging effects of IR (Figure 5).   Other 
groups have reported an intrinsic resistance to DNA damaging agents in G1, as 
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well as an augmented rate of DNA repair in this phase of the cell cycle (114, 
115).  While a reduced susceptibility to IR-induced DNA damage in G1 could 
partially explain the radioprotection we observe, such an explanation, however, 
cannot account for the radiomitigation effects of PQ in vivo, where G1 arrest after 
IR exposure is protective.  
Prevention of G1-S traversal is an alternative mechanism that can explain 
the radiomitigation effects of CDK4/6 inhibitors.  Attempted G1-S traversal in the 
setting of unrepaired DNA damage is a particularly toxic event (80, 116), likely 
due to activation of early S-phase transcription factors such as the E2Fs which 
regulate many effectors of apoptosis (117, 118).  This mechanism is consistent 
with increased radiosensitivity noted in late G1 (66, 67), more recently described 
as damage occurring after the G1 restriction point (119, 120).  Additionally, it may 
be that certain types of IR-induced lesions (single strand breaks (SSBs) or more 
rarely inter-strand crosslinks (ICLs)) are relatively non-toxic in G1 (121), but 
become more toxic in S-phase as these lesions are converted to toxic DSBs (e.g. 
through stalled replication forks).  Indeed, although DSBs are highly correlated 
with cytotoxicity, approximately 90% of DNA lesions after IR are SSBs (122), 
while ICL may also be induced at lower frequency by IR (59).  Therefore, 
inhibiting G1-S traversal may be beneficial by preventing apoptosis associated 
with E2F induction, or by allowing time for repair of lesions that are well-tolerated 
during G1, but which may be converted to more toxic DSBs during S-phase. 
We believe prevention of G1-S traversal explains how selective CDK4/6 
inhibitors improve survival when administered concurrent with or up to 20 hours 
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after exposure to lethal IR (Figure 17).  This mechanism is additionally supported 
by the requirement for induction of p21CIP for optimal survival after IR (Figure 15).  
Expression of p21CIP peaks 24-48 hours after IR exposure (123), and mice 
lacking p21CIP are sensitive to the hematologic toxicities of IR (Figure 15).  
Therefore, a cell cycle pause induced by p21CIP hours after IR ameliorates the 
hematopoietic toxicity of IR.  Additional support for this view is provided by the 
recent finding that FBXO31 expression is required for maximal radioprotection 
post-IR (71).  Like p21CIP, FBXO31 expression is induced after IR in an ATM-
dependent manner, and its expression induces degradation of cyclin D1, thereby 
reducing CDK4/6 activity and inducing a G1 arrest in some cell types.  Therefore, 
a maximal G1 arrest effected by disparate mechanisms post-IR appears 
beneficial for survival.  Additionally, the G1 arrest induced in HSPC by anti-
proliferative mechanisms like p21CIP post-IR does not appear complete, in that it 
can be further enhanced by PQ (Figure 15).   
Current clinical interventions to mitigate radiation toxicity have relied on a 
combination of supportive care, growth factors, cytokines, and specific chelating 
agents – none of which are effective when administered several hours after 
radiation exposure (reviewed in (103)).  While growth factor support with agents 
such as G/GM-CSF or erythropoietin has been shown to attenuate the toxic 
effects of DNA damaging agents (107, 124), the small molecule PQ approach 
appears superior in magnitude of effect, has a longer effective duration after 
exposure, and protects without the significant expense and toxicities of these 
biologics.  Small molecule CDK4/6 inhibitors are orally bioavailable and can be 
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readily stockpiled, both highly desirable features for agents to be used in the 
setting of a radiologic disaster.  Moreover, PQ ameliorates DNA damage-induced 
thrombocytopenia (Figure 12), a significant unmet need in clinical oncology and 
radiation mitigation.  While late hematological toxicity has been associated with 
growth factor support after exposure to DNA damaging agents in both humans 
(125, 126) and mice (107), PQ does not appear to augment late hematological 
toxicity after TBI (Figure 16).  Furthermore, growth factor support and PQ appear 
to enhance count recovery through different mechanisms: the former by inhibiting 
apoptosis, increasing HSPC proliferation and modulating lineage choice; the 
latter by promoting DNA repair prior to a resumption of progenitor proliferation.  
Therefore, we think it likely that the combined use of PQ and growth factor 
support may prove particularly beneficial in ameliorating myelosuppression 
resulting from the exposure to DNA damaging agents.   
In addition to providing radiomitigation, PQ could also be employed as an 
adjuvant to clinical anti-cancer therapy.  Although cell cycle alteration has 
successfully improved survival from lethal IR in the past (110, 111), prior 
strategies possessed limited clinical utility due to the lack of selective alteration of 
the cell cycle in the bone marrow without affecting tumors.  The PQ approach 
capitalizes upon the relatively infrequent requirement for CDK4/6 activity for 
tumor maintenance in order to selectively radioprotect hematopoietic progenitors 
(Figure 12); thereby improving survival after IR without compromising tumor kill 
(Figure 17).  Preventing myelosuppression after cytotoxic cancer therapies would 
allow increased dose intensity and density, allowing increased tumor kill.  Our 
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data do suggest, however, that PQ would compromise tumor kill in cancers that 
are sensitive to CDK4/6 inhibition, although we believe this concern would not 
apply to most human malignancies.  For example, CDK4/6 inhibitors failed to 
induce G1-arrest in Rb-deficient small cell lung cancer cell lines, and therefore 
PQ would be unlikely to compromise chemotherapeutic efficacy in the ~10% of 
human cancers that are Rb-deficient.  A similar logic applies to cancers with 
other genetic lesions that render them insensitive to CDK4/6 inhibition (e.g., Myc 
activation).  Importantly, even some tumors (e.g. TyrRas p16INK4a/Arf-/- 
melanoma) whose progression is facilitated by inactivation of p16INK4a, an 
endogenous CDK4/6 inhibitor, were not protected by CDK4/6 inhibitors at the 
time of IR exposure (Figure 17).  Therefore, it is likely that PQ could attenuate 
the hematological toxicity of anti-cancer therapies in a substantial fraction of 
human cancer patients without a concomitant diminution in anti-cancer efficacy. 
 CDK4/6 inhibitors are in an advanced stage of clinical development as 
anti-neoplastics. PD0332991 has been administered to humans (100, 101), and 
five current phase I/II trials with this compound are planned or underway testing 
(listed at clinicaltrials.gov as NCT00555906, NCT00420056, NCT00721409, 
NCT00141297 and NCT01037790).  Several other series of selective CDK4/6 
inhibitors have been reported (127), with at least two additional candidates slated 
to soon enter human phase I trials.  Therefore, we believe the ready availability 
of these relatively non-toxic, small molecule inhibitors with favorable 
pharmacology in humans will allow for human testing of the beneficial effects of 
PQ after TBI and DNA damaging agents in short order.   
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E.  Materials and Methods 
 
Animals:  All animal experiments were performed in accord with the UNC 
Institutional Animal Care and Use Committee.  Young adult (8-12 weeks of age) 
C57Bl/6 (Jackson Labs), C3H (Harlan Sprague-Dawley), FVB/n TyrRAS+ 
p16INK4a/Arf-/-, and p21CIP-/- mice (from Hanno Hock, Massachusetts General 
Hospital and Jackson Labs) fully backcrossed (N=10 generations) C57Bl/6 were 
studied.  Peripheral blood was collected by tail vein nick for CBCs (HemaTrue, 
Heska).  Experiments on tumor-bearing TyrRAS+ p16INK4a/Arf-/- mice (108) were 
performed in males fully backcrossed (N>10) to the FVB/n background. Mice 
were treated as previously described (88) with PD0332991 (Pfizer) given by oral 
gavage at a dose of 150 mg/kg BW. TyrRAS+ p16INK4a/Arf-/- mice were serially 
observed for tumor development.  When tumors were noted to be ~0.2 cm2 in 
size, animals were treated as described and tumor response assessed by daily 
caliper measurements.    Data in Figure 17 are normalized to tumor size at the 
time of therapy initiation, with volumes calculated using the formula (w x l)2 / 2. 
Tumor-bearing mice were euthanized at the indicated times for morbidity, tumor 
ulceration, or tumor size >1.5 cm in diameter. 
Ionizing radiation sources:  Animals were irradiated using a 137Cs AECL 
GammaCell 40 Irradiator (Atomic Energy of Canada), or using a XRAD320 
(Precision XRay Inc.) biological irradiator.  Experiments were carried out using 
the 137Cs source unless otherwise noted.  Our empirically determined LD90 in this 
system was 7.5 Gy, consistent with prior studies (72, 104, 107, 124). 
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Cell Lines, γH2AX by Flow Cytometry, WST-1, Western Blots:   
Telomerized human diploid fibroblasts (tHDF; from Gordon Peters) were cultured 
in DMEM +10% FBS with any additional compounds.  The same conditions were 
used for A2058 and WM2664, human melanoma cell lines with known Rb-
pathway mutations: A2058 is Rb-null, whereas WM2664 lacks p16INK4a/Arf (128).  
For γH2AX assay, cells were fixed, permeabilized, and stained with anti-γH2AX 
as per γH2AX Flow Kit (Millipore).  Cell viability was assessed using a 
colorimetric assay for cleavage of water soluble tetrazolium salt (WST-1 assay; 
TaKaRa Bio USA), performed by seeding 1x103 cells per well in a 96-well tissue 
culture plate in 100 μL of growth medium and treating as indicated with CDK4/6 
inhibitor (100 nM PD0332991 or 2 μM 2BrIC) and radiomimetic (1 μM 
doxorubicin).  Following treatment cells were allowed to recover for 7 days in 
normal growth medium, and then cell number was quantified using the WST-1 
assay.  For cell number and viability measured by CellTiter-Glo Luminescent Cell 
Viability Assay (Promega), cells were seeded overnight, incubated for 16 hrs with 
CDK4/6 inhibitor, and next incubated for 8 hrs with CDK4/6 inhibitor and 
doxorubicin.  Fresh media was then added and cell number and viability were 
quantified 5 days later.  γH2AX levels were assessed by flow cytometry after 
fixation and anti-γH2AX-FITC incubation (Millipore).  Western blots were 
performed on cell lysates in NP-40 lysis buffer with protease inhibitors (Roche) 
and phosphatase inhibitors (Calbiochem) as previously described (88), using 
anti- p53-phospho-Ser15 (Cell Signaling), Bax, and actin-HRP (Santa Cruz). 
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Comet Tail Assay after IR:   tHDF received 6 Gy IR from a RS2000 
Biological Irradiator (RadSource Inc) with or without 24 hours of prior exposure to 
100nM PD0332991.  Cells were placed on ice 5 minutes after IR and processed 
as previously described (129) prior to electrophoresis with SYBR Green (Applied 
Biosystems), imaged as for γH2AX (see below) and quantified using Comet 
Score software (TriTek Co). 
γH2AX and Clonogenic Assay after IR:   For γH2AX images, tHDF 
received 6 Gy IR with or without 24 hours of prior exposure to 100nM 
PD0332991.  5 minutes after IR, cell were washed 2x with ice cold PBS, fixed 
with 4% paraformaldehyde + 0.1% Triton-X (Sigma) for 30 min, washed 2x with 
ice cold PBS, incubated with anti-γH2AX-AlexaFluor488 (Cell Signaling) and 
phalloidin-AlexaFluor568 (Invitrogen) for 1 hour, washed 4x with ice cold PBS, 
and mounted.  Images were captured using a mercury laser attached to an 
inverted microscope (model IX-81, Olympus) equipped with a 20× PlanApo 
objective or a 40× PlanApo objective, a CCD camera (model C4742-80-12AG, 
OCAR-ER, Hamamatsu), controlled by Slidebook software.  Mean nuclear 
intensities were computed in ImageJ software.  The clonogenic assay was 
performed as previously described (130), with cells plated in a six-well plate 6 
hours prior to treatment with 100nM PD0332991 for 24 hours, with 6 Gy IR 
occurring 12 hours after drug exposure. 
Compounds:  R547 (94) was synthesized by the Center for Integrative 
Chemical Biology and Drug Discovery (CICBDD).  2BrIC was synthesized by 
OTAVA Chemicals based on compound 4d from series shown in reference (92).  
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PD0332991 (90, 91) was provided by Pfizer, Inc, or synthesized by the CICBDD.  
Flavopiridol (95) was purchased from Sigma-Aldrich Co.  Roscovitine (93) was 
purchased from LC Laboratories. 
BM-MNC Isolation and CAFC Assay:  BM-MNC isolation and CAFC 
assays were performed as previously described (131). Briefly, BM was harvested 
from femurs and tibias of mice and centrifuged to purify BM-MNCs. The 
frequencies of CAFC were determined at weekly intervals (on day 7, 14, and 35). 
Wells were scored positive if at least one phase-dark hematopoietic clone 
(containing 5 or more cells) was seen. The frequency of CAFC was then 
calculated using L-Calc software (StemCell Technologies) for limiting dilution 
analysis.  
Bone Marrow Immunophenotyping and Proliferation by Flow Cytometry:  
For HSPC proliferation experiments, mice received daily oral gavage with 
PD0332991 for 2 days with 1 mg BrdU intraperitoneal injection every 6 hours for 
24 hours prior to sacrifice.  BM-MNC harvest and immunophenotyping was 
performed using RBC lysis, biotin-conjugated Lin-panel incubation (Invitrogen), 
paramagnetic bead-conjugated streptavidin (Miltinyi) incubation, and magnetic 
depletion using an AutoMACS (Miltinyi).  At least 2x106 Lin-depleted cells per 
mouse were incubated with fluorescently labeled antibodies against cell surface 
antigens used to identify hematopoietic progenitor subpopulations as previously 
described (37, 40): CD34-FITC, CD16/32-PacificBlue, IL7Ra-PE-Cy5, and cKit-
APC-Alexa750 from eBiosciences; Sca1-PE-Cy7, CD150-PE-Cy5, and CD48-
PacificBlue from BioLegend; and Aqua Live/Dead viability dye (Invitrogen).  
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Streptavidin-PE-TexasRed (Invitrogen) was used to confirm efficiency of lineage-
depletion (not shown).  After cell surface staining, cells were fixed, 
permeabilized, and stained with antibodies against Ki67-FITC, BrdU-APC, and 
caspase3-PE (BD Biosciences). In all experiments, gating based on isotype 
controls was used as appropriate (not shown). Flow cytometry was performed 
using a CyAn ADP (Dako) and analyzed with FlowJo software (Tree Star).  For 
each bone marrow sample, a minimum of 200,000 cells were analyzed using 
FlowJo software (TreeStar). For cell culture samples, a minimum of 20,000 cells 
were analyzed. 
Statistical Analysis:  Unless otherwise noted, comparisons are made with 
one-way ANOVA with Bonferroni correction for multiple comparisons where 
appropriate, and α<0.05 is considered statistically significant.  Error bars are +/- 
standard error of the mean (SEM). 
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Figure 3:  Cell cycle dose-response after 24 hours of CDK inhibitor 
treatment. Dose-response curves to various CDK inhibitors. Representative cell 
cycle dot-plots.  Cells were treated for 24 hours at the indicated dose prior to 15 
minutes BrdU pulse, cell harvesting, fixation, staining, and analysis by flow 
cytometry. 
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Figure 4:  Cell cycle after 24 hours of CDK inhibitor treatment at a single 
concentration.  Representative cell cycle dot-plots.  Cells were treated for 24 
hours prior to 15 minutes BrdU pulse, cell harvesting, fixation, staining, and 
analysis by flow cytometry. 
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Figure 5:  PQ enhances radioresistance in vitro. (A) 40x images of phospho-
γH2AX foci (green) and phalloidin staining (red) of tHDF +/- 6 Gy IR and 24 hours 
of 100 nM PD0332991 exposure.  Scale bar = 50 μm.  (B) Western blots showing 
phospho-p53 induction in tHDF lysates after 6 Gy IR with and without 
PD0332991 treatment.  (C) Comet tail area with 24 hours in 100 nM PD0332991 
prior to indicated IR dose.  40 cells in each condition were imaged at 20x 
magnification.   *p<0.01, **p<0.0001 for pair-wise comparisons. 
 
 
 
 
Figure 6 :  PQ enhances resistance to radiomimetic doxorubicin in vitro. 
(A) In vitro schedule of CDK inhibitor and doxorubicin exposure using tHDFs.  
Assays performed as indicated on the timeline.  (B) Flow cytometry analysis of 
phospho-γH2AX formation after PD0332991 and doxorubicin treatment in tHDFs.  
(C) Western blot analysis of DNA damage response markers in tHDFs at 
indicated times after PD0332991 +/- doxorubicin treatment.  (D) WST assay for 
cell proliferation at 7 days after doxorubicin exposure.  All absorbances are 
normalized to DMSO.  *p<0.01, **p<0.001, ***p<0.0001, n.s. is non-significant for 
the indicated pair-wise comparisons.  
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Figure 7:  In vitro protection from genotoxic agents using PQ. (A) 
Quantification of mean nuclear intensity from γH2AX immunofluorescence 
images with and without 6 Gy IR.  N=139 or greater for each condition; box = 
middle 50%, whiskers = 0-25% and 75-100%.  Significance determined by 
Kruskal-Wallis (p<0.0001) with Dunn post-hoc test.  (B) Flow cytometry analysis 
of γH2AX formation after 2BrIC and doxorubicin treatment in tHDFs.  (C) Comet 
tail area with 24 hours in 1 µM 2BrIC prior to indicated IR dose.  40 cells in each 
condition.  (D) Quantification of P53-Ser15-phosphorylation from western blots 
normalized to actin.  (E) Ratios of colony formation per cell in clonogenic assays 
after IR with or without PD0332991. *p<0.01, **p<0.0001 for pair-wise 
comparisons.  
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Figure 8:  In vitro protection of cell number from doxorubicin toxicity using 
PQ.  (A) Quantification of WST assay in tHDFs, WM2664, and A2058 cell lines 1 
week after 1 uM doxorucin exposure using 2BrIC.  Other CDK4/6 inhibitors (B) 
flavopiridol, (C) roscovitine, and (D) R547 were assessed for their ability to 
protect from doxorubicin exposure using CellTiter Glo assay.  For (B), (C), and 
(D), doxorubicin concentrations were 122 nM for A2058 and WM2664, and 370 
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nM for tHDF.  #p<0.01 vs. DMSO, ##p<0.001 vs. DMSO, *p<0.01 vs. Dox, 
p<0.001 vs. Dox. 
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Figure 9:  CDK4/6 inhibition decreases HSPC proliferation. (A) Flow 
cytometry gating scheme for HSC and MPP (top), and myeloid progenitors 
(bottom) using cell surface antigens.  (B) Representative contour plots of 
proliferation in indicated HSPC populations by BrdU incorporation and Ki67 
expression after 48 hours of no treatment (N=6) or PD0332991 treatment (N=6) 
in the presence of 24 hours of BrdU.  Contours represent 5% density.  (C) 
Quantification of BrdU and Ki67 data in all HSPC subpopulations.  (D) Relative 
frequency of Lin-, HSC, MPP, or Lin- cKit+ Sca1- populations after 48 hours of 
D0332991 treatment and 24 hours of BrdU exposure.  *p<0.05, **p<0.01, 
*p<0.001. 
 
 
P
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Figure 10: Apoptosis, viability, CAFC, and oligopotent progenitor 
population frequencies after CDK4/6 inhibitor treatment. (A) Total BM-MNC 
counts from mice exposed to 48 hours of CDK4/6 inhibitor treatment.  Caspase3 
and viability of total Lin- cells (B) and HSC (C) with and without 48 hours of 
PD0332991 exposure and 24 hours of BrdU pulse.  (D) Frequency of Lin- cells of 
myeloid, erythroid, and lymphoid progenitors after 48 hours of CDK4/6 inhibition. 
(E) CAFC results at 1, 2, and 5 weeks after 48 hours of PD0332991 treatment 
and bone marrow harvest without BrdU exposure. 
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Figure 11:  Chronic CDK4/6 inhibition induces mild, reversible 
myelosuppression. Daily oral gavage with PD0332991 for 12 days with 
complete blood counts (CBCs) at indicated time points. Data are shown as a 
moving average with each point representing the mean of three consecutive 
CBCs. Solid black bar indicates duration of PD0332991 treatment.  
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Figure 12:  PQ at the time of TBI increases survival. (A) Treatment schedule 
with PD0332991 in initial radio-protection experiments. (B) Kaplan-Meier analysis 
of survival after 7.5 Gy of TBI with or without PD0332991 treatment. (C) Survival 
after 7.5 Gy TBI with the indicated dosing schedules of PD0332991.  (D) 
Aggregate results of animals gavaged -4 hours prior to TBI, representing results 
from three murine strains with animals of both sexes. Results of strains 
considered independently were comparable in all groups.  All survival curve p-
values calculated by the log-rank test as a pair-wise comparison with the 
untreated group. (E) Caspase activation in BM-MNCs after exposure to 7.5 Gy 
TBI (X-Rays; see methods). (F) Complete blood counts with differential at 21 
days after 7.5 Gy TBI with and without PD0332991 treatment. Treated animals 
received PD0332991 by oral gavage at -28, -4, and +20 hrs relative to IR dose 
on day 0. Myeloid cells includes granulocytes and monocytes. # indicates that 
the maximum value of the cohort is shown in lieu of error bars where cells 
numbers were too few to reliably quantify.  *p<0.05, **p<0.01, ***p<0.001. 
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Figure 13: CDK4/6 inhibition improves radiation survival in different inbred 
strains. . (A)  Survival of adult female C57Bl/6 mice after 8.5 Gy TBI.  (B) 
Survival of adult female C57Bl/6 mice after 6.5 Gy TBI.  (C) Survival of adult 
female CH3 mice after 7.5 Gy TBI.  All p-values determined using the log-rank 
test.  
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Figure 14: Brief PQ at the time of TBI attenuates myelosuppression and 
augments count recovery after sublethal ionizing radiation. Weekly CBCs 
on tail vein bleeds of PD0332991 treated and untreated mice after 6.5 Gy TBI, a 
sub-lethal dose. Asterisk(s) indicate statistical significance determined by a 2-
sided t-test.  
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Figure 15:  p21CIP and CDK4/6 inhibition both enhance IR survival.  Kaplan-
Meier survival curves for mice wild-type, heterozygous, or null for p21CIP exposed 
to lethal TBI four hours after oral gavage with (A) vehicle or (B) PD0332991.  
Mice were irradiated using an X-Ray source (see Methods).  Log rank test for 
trend is shown. 
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Figure 16:  Hematologic profiles are unchanged >100 days after sublethal 
IR exposure.  Results of complete blood counts with differential at 143-242 days 
after 6.5 or 7.5 Gy TBI with and without PD0332991 treatment are shown and 
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compared to age-matched unirradiated, untreated animals. Myeloid cells = 
granulocytes + monocytes.  
Figure 17:   CDK4/6 inhibition improves survival in mice with melanomas. 
(A) Representative images of the progression of an autochthonous TyrRas 
p16INK4a/Arf-/- melanoma despite daily oral therapy with PD0332991. (B) 
Tumor growth with or without continuous daily PD0332991 treatment compared 
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to tumor growth with or without PD0332991 administered as a single dose 4 
hours prior to 7.5Gy TBI.  n.s.=non-significant.  (C) Kaplan-Meyer survival curves 
showing overall mortality, and mortality subdivided by cause. P-values calculated 
using the log-rank test. 
 
 
Figure 18:  In vivo radioprotection of tumor-bearing mice using PQ. 
Bodyweights in mice with autochthonous melanomas with or without a single 
dose of PD0332991 at -4 hours prior to 7.5 Gy TBI.  *p<0.05.  
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Chapter 
 IV. Supporting data for CDK4/6 radioprotection 
  
 
 
 
 
 
 
 
 
 
 
 
 Though the survival benefit of PQ for radioprotection in vivo is striking, 
many mechanistic details remain unclear.  Additionally, mechanisms of 
radioprotection need not be identical to mechanisms of radiomitigation, and the 
differences between the two may inform future optimization of radiomitigation. 
A.  Reproducibility of PQ in vitro 
 While the prior studies focused on WM2664, A2058, and tHDF, it is 
important to note that CDK4/6 inhibition is effective in additional human 
melanoma line SKMel173, whereas inhibition with PD0332991 has no effect on 
SKMel28 or PMWK cell lines (Figure 19).  And in confirmation of data already 
presented (Figure 3Figure 4), a detailed test of PQ with 2BrIC is observed to 
produce cell cycle effects highly similar to those of PD0332991 in WM2664 and 
A2058 (Figure 20).  These data add additional evidence for the consistent G1 
arrest achieved after CDK4/6 inhibition in dependent cell lines, while CDK4/6 
independent cell lines remain unaffected (Figure 3Figure 4).  Also, these results 
are in concordance with genetic data in vivo showing that some cells can 
proliferate entirely independently of CDK4/6 activity (11, 15). 
B.  Kinetics of PQ 
Though any number of cell lines have yet to be tested for the effects of 
CDK4/6 inhibition, the kinetics of G1 arrest are particularly important for 
scheduling optimal PQ relative to IR exposure.  In tHDF, the majority of cells 
have arrested in the G1-phase after 8 hours of CDK4/6 inhibition with 
PD0332991, and G1 arrest is nearly complete after 12 hours (Figure 21).  A cell 
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survival benefit is observed when tHDF are irradiated after 12 or more hours of 
CDK4/6 inhibition (Figure 7), but radioprotection is not observed when cells are 
irradiated prior to CDK4/6 inhibition (not shown).  These data suggest that the 
percentage of target cells in G1 arrest at the time of IR exposure should be 
maximized for optimal benefit. 
In vivo, cell cycle arrest kinetics differ from in vitro administration of 
CDK4/6.  Oral administration requires absorption of the drug prior to maximal 
plasma concentrations, and the duration for which plasma drug levels remain 
above the target tissue IC50 determine the cell cycle effects.  In vivo, maximal 
plasma levels of PD0332991 are observed 60-90 minutes after oral gavage, and 
levels remain high for at least 12 hours, and possibly longer than 24 hours 
(Figure 22). 
Equally important to the kinetics of G1 arrest is the timing of re-entry into 
the cell cycle and progression to S-phase after CDK4/6 inhibition is ceased.  
CDK4/6 inhibitors are reversible, both in vivo and in vitro (Figure 23).  In vivo, 
bone marrow resumes normal proliferation rates within 48 hours after a single 
oral dose of PD0332991.  In vitro, the majority of tHDF have resumed the cell 
cycle by 12 hours after switching to media without CDK4/6 inhibitors, regardless 
of the duration of cell cycle inhibition (12 vs. 24 hours).   
C.  DDR during PQ 
Though radiomitigation has not yet been achieved in vitro with PQ, 
studying the DDR in these cell lines may aid the understanding of how PQ is 
achieving radiomitigation in vivo.  First, we examined the kinetics of the DDR in 
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tHDFs after IR at doses where PQ is radioprotective.  In concordance with prior, 
more detailed studies of the DDR, ATM was phosphorylated rapidly after 3 or 6 
Gy IR, and remained active for at least 24 hours (Figure 24).  CHK2 was 
phosphorylated equally rapidly and more robustly, but phosphorylation declined 
rapidly after IR.  Phosphorylation of p53 peaked at least 6 hours after IR, and 
levels remained elevated for at least 24 hours after 3 Gy, and at least 48 hours 
after 6 Gy. 
We next sought to examine this same signaling pathway in tHDF treated 
with PD0332991 for 24 hours before and after IR.  Surprisingly, the treated cells 
demonstrated very little change in ATM activation relative to untreated cells, yet 
detectable reductions in downstream CHK2 and p53 activation were seen, even 
at the lowest IR dose (Figure 25Figure 26).  
It is likely that the observed reduction in ATM, CHK2, and p53 activation 
24 hours after IR reflects increased DNA damage repair in the PD0332991 
treated cells.  These results could also be explained by alterations in the function 
of ATM or ATR during CDK4/6 inhibition, though ATM and ATR are not known 
targets of CDK4/6 or CDK2.  Furthermore, MEFs lacking CDK4, CDK6, and 
CDK2 (triple knock-out) show no deficits in DNA damage response during G1 
after IR (76), which strongly suggests that inhibiting only CDK4/6 
pharmacologically does not directly alter ATM or ATR responses to DNA 
damage.  Further analysis of DDR in the setting of CDK4/6 inhibition is 
necessary to better elucidate the molecular mechanisms effecting the increased 
cellular survival after IR. 
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D.  Summary:  Supporting data for CDK4/6 radioprotection 
These additional studies provide a greater understanding of how the 
timing of PQ relative to IR influences radioprotection efficacy.  Progression of the 
target cell type through the cell cycle likely determines the latency between 
CDK4/6 inhibition and maximal G1 arrest of a population of cells.  In vivo 
pharmacokinetics must also be considered.  The kinetics of the DDR also may 
influence the ability of PQ to provide maximal radioprotection, and further studies 
are needed to elucidate how PQ may be influencing different stages of DDR 
signaling cascades. 
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Figure 19:  Cell cycle profile dose-response curves of selected human cell 
lines to incubation with PD0332991.  Cells were exposed for 24 hours to doses 
of PD0332991 with a 15 minute pulse in 10 µM BrdU prior to fixation and flow 
cytometry for cell cycle analysis.  Error bars show SEM of each point measured 
in triplicate.  We have data from 7 additional cell lines (not shown). 
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Figure 20:  Representative dot-plots showing cell cycle of human 
melanoma lines WM2664 and A2058 at decreasing doses of 2BrIC.  Cells 
were exposed for 24 hours to doses of 2BrIC with a 15 minute pulse in 10 µM 
BrdU prior to fixation and flow cytometry for cell cycle analysis.  A clear G1 arrest 
is apparent after 2.6 µM 2BrIC treatment in CDK4/6-dependent WM2664 cells, 
but has no cell cycle effect in Rb-null A2058 cells. 
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Figure 21:  Cell cycle kinetics in tHDF after 100 nM PD0332991 treatment.  
Cells were exposed for the time shown to doses of PD0332991 prior to a 15 
minute pulse in 10 µM BrdU followed by fixation and flow cytometry for cell cycle 
analysis.  Error bars show SEM of each point measured in triplicate.  
Representative dot-plots are shown in (A) and the cell cycle stages at each 
timepoint are plotted in (B). 
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 Figure 22: Pharmacokinetics of PD0332991 in mice.  Seven C57Bl/6 mice 
were administered 150 mg/kg of PD0332991 in a 50 mM sodium lactate buffer 
solution by oral gavage at 0 hours.  At each timepoint blood was collected from 3 
mice by tail vein nick.  Plasma was separated by centrifugation, purified by 
precipitating and discarding protein, and stored for analysis after the final 
timepoint by high pressure liquid chromatography and tandem mass 
spectrophotometry. 
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Figure 23:  Reversibility of CDK4/6 inhibition.  (A) Murine Lin- cKit+ Sca1+ 
cells were isolated at given times after a single dose of 150 mg/kg PD0332991 
and with 16 hours of EdU exposure to mark proliferating cells.  Error bars show 
SEM of N=3 per timepoint. (B) tHDF cells were given fresh media after 12 or 24 
hours of inhibition with 100 nM PD0332991, pulsed with 10 µM BrdU, fixed, and 
analyzed by flow cytometry.  Mean percentage of cells in S-phase at each 
timepoint is shown. 
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Figure 24:  Time course of DDR after IR in tHDF.  Cells were irradiated with 0, 
3, or 6 Gy X-rays prior to harvest and lysis at the time indicated. 
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Figure 25: DDR with and without PQ after IR.  tHDF were grown with or 
without 200 nM PD0332991 for 24 hours prior to IR.  Cells were then grown in 
fresh media with or without PD0332991 for 24 hours prior to harvest and lysis.   
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Figure 26:  Quantification of DDR with and without PD0332991.  
Quantification of the western blots shown in Figure 25, measured by digital 
densitometry normalized to actin levels in each lane. 
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Chapter 
 V. Clinical relevance and applications of CDK4/6 inhibition 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As mentioned above, CDK4/6 inhibition is likely to be used in the clinic in 
the near future, but is currently being explored for efficacy as a direct antitumor 
agent.  Because one such CDK4/6 inhibitor, PD0332991, has already been found 
to be safe for use in humans (100, 101), off-label uses for PD0332991 will be 
available to clinicians if PD0332991 gains FDA approval.  Possible clinical uses 
are as follows. 
A.  Accidental radiological exposure casualty mitigation 
 Human exposure to lethal levels of IR is historically uncommon, though 
nuclear warheads, “dirty bombs,” and improvised nuclear devices continue to 
present a high risk of mass casualties for which governments and hospitals must 
prepare.  At present, treatment of high-dose IR exposure in humans is limited to 
supportive care (132), including intravenous fluids, antibiotics, and recombinant 
cytokines and growth factors.  Other than these symptomatic treatments, no 
other agents administered after IR are known to improve survival in humans.  
Importantly, none of the measures currently used to treat acute radiation 
sickness address the DNA lesions caused by IR.   
Recent research has revealed a number of radioprotective agents (133), 
but none are effective when administered well after IR exposure.  Perhaps the 
most promising radioprotectant strategy is a TLR-5 agonist protein which has 
proved to be highly radioprotective in mice and rhesus macaques (102), though 
its effectiveness is marginal (<40% of maximum) when delivered even 1 hour 
after IR.   Antioxidant strategies also have some benefit as radioprotectants (e.g., 
amifostine;(134)), presumably by limiting the secondary DNA damage caused by 
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the formation of free radicals, but have no benefit when administered after IR 
exposure. Here, CDK4/6 inhibitors represent a novel class of compounds that 
effectively allow increased repair of DNA damage well after IR exposure; CDK4/6 
inhibitors are true radiomitigants.  Because PD0332991 is orally bioavailable, 
stable at room temperature, and easily stockpileable, it represents a feasible 
treatment after a radiological accident.  Most importantly, because PD0332991 is 
effective when delivered well after IR exposure (at least 20 hours), the increased 
window of time for effective radiomitigation makes its successful application in 
the field far more likely.  
One potential limitation, however, is that the range of IR doses for which 
CDK4/6 inhibition may be effective is likely quite narrow.  In cells, there is no 
benefit to CDK4/6 inhibition beyond 9 Gy, and clearly the benefit in mice is 
diminished at 8.5 Gy relative to the impressive survival benefic at 7.5 Gy.  
Exposures during a nuclear bomb detonation could vary from 0-10,000 Gy 
depending on the distance from the detonation source, and CDK4/6 inhibition 
would likely have no effect on other consequences of such an explosion such as 
burns or other physical trauma.  Additional testing in non-human primates may 
reveal the maximal IR dose for which CDK4/6 would be effective, especially 
when combined with optimal supportive care strategies. 
B.  Increased therapeutic IR delivery and increased chemotherapy 
 CDK4/6 inhibitors may find much more widespread use in oncology. Over 
13,000 patients were diagnosed with some form of cancer in 2007, and 
approximately half of these patients received some form of radiotherapy during 
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the course of their treatment (135).   Not only do a large number of patients 
receive radiotherapy annually, but many of the most common cancers are treated 
with radiation (e.g., breast and lung cancer).  CDK4/6 inhibition is of potential use 
in patients receiving radiotherapy, where myelosuppression is the dose-limiting 
toxicities of IR treatment.  By reducing myelosuppression, CDK4/6 inhibition 
would increase the tolerated IR dose, thus increasing the tumor cell kill of a given 
treatment.  Breast cancer, pancreatic cancer, and lung cancer are commonly 
treated with total doses of 40-70 Gy, subfractionated into ~1.8-2 Gy doses (Chris 
Bakkenist, personal communication).  These IR exposures are within a range 
where CDK4/6 inhibition is likely to have a beneficial effect in the HSPC.  
Obviously this strategy will only be effective in therapeutic situations where 
myelosuppression is the dose-limiting toxicity, and not xerostomia or 
gastrointestinal damage.   
C.  Prevention of treatment-induced malignancies 
Radiation induced secondary malignancies are not uncommon, and is of 
particular concern in young patients because the longer duration of survival post-
exposure (136-138).  Although the long-term consequences of CDK4/6 inhibition 
were not exhaustively studied in this work, CDK4/6 inhibition may reduce the 
likelihood of radiation-induced secondary because it ameliorates DNA damage.  
By the same reasoning, if PQ may also prevent secondary malignancies in 
patients receiving chemotherapy.  Many secondary malignancies after 
chemotherapy are of hematologic origin (139), suggesting the CDK4/6 inhibition 
might be particular effective at reducing this risk. 
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Even more patients could benefit if the strategy was expanded to include 
patients exposed to high IR doses during routine imaging procedures.  Notably, 
fluoroscopy and repeated computerized tomography scan deliver high IR dose to 
patients and measurably increase the risk of radiation-induced malignancy (140).  
An enormous number of patients undergo these procedures annually, though 
increased absolute risk is often low (140, 141).  The most likely to benefit would 
be to those patients who receive IR at a young age, or those who receive greater 
cumulative IR exposure.   Future research should focus first on quantifying the 
risk of radiation induced malignancies from such procedures, followed by tests of 
CDK4/6 inhibition to limit unwanted outcomes of radiotherapy. 
E. Summary:  Clinical applications of CDK4/6-mediated PQ 
CDK4/6 inhibition causes PQ in the HSPC of mammals, which renders the 
HSPC radioresistant.  Radioresistance is beneficial during radiotherapy, and 
radiomitigation can be achieved after accidental nuclear exposure.  Potential 
future applications include PQ to prevent myelosuppression during 
chemotherapy, as well as PQ to prevent secondary malignancies caused by 
radiation exposure from imaging applications or from chemotherapy. 
 
 
 
 
 
 
Chapter 
VI. Conclusions and Remaining Questions
 
 
The studies presented in this thesis explored the use of CDK4/6 inhibitors 
to specifically inhibit proliferation in the hematopoietic system, thereby protecting 
it from IR damage.  These studies have advanced scientific understanding of 
HSPC biology, of the molecular underpinnings of the cell cycle, and of 
radioprotection strategies in mammals.  
A. HSPC dependence upon CDK4/6 
Prior studies demonstrated that murine hematopoiesis during fetal 
development relies upon CDK4/6 activity (11, 15).  Because fetal hematopoiesis 
differs from adult hematopoiesis, it was not clear from these germline knockout 
studies whether adult murine hematopoiesis also shared a dependence upon 
CDK4/6.  The work presented here has clearly demonstrated that adult murine 
hematopoiesis does indeed depend on CDK4/6 activity (Figure 9) and can be 
reversibly slowed using small molecule CDK4/6 inhibitors. 
B.  PQ increases radioresistance and can achieve radiomitigation 
The most important contribution of this work is to the field of 
radioprotection.  Though other radioprotectant strategies exist (133), 
radiomitigants have proven difficult to identify.  Furthermore, no other 
radioprotection strategies work through enhancing endogenous DNA repair 
mechanisms.  Furthermore, the PQ strategy is selectively beneficial in HSPC, 
while other radioprotection mechanisms are not able to selectively benefit stem 
cell compartments.  Such a strategy not only enables enhanced survival acutely 
after IR exposure, but also may enhance survival long term by protecting the 
HSPC. 
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C.  Optimization of CDK4/6 inhibition radiomitigation 
The work here has been performed only in human cells and in mice, so 
there may be some optimization that is required to find the ideal dose, schedule, 
and timing for use in humans.  Additionally, it remains to be seen how best to 
combine CDK4/6 inhibition with current treatments for acute radiation sickness.  
The combination of CDK4/6 inhibition with growth factors is of particular interest, 
since there is likely an ideal and sequential way to combine the two strategies:  
CDK4/6 inhibition could be used to optimize DNA damage repair initially after the 
IR exposure, followed by growth factor support to encourage hematopoiesis once 
the majority of the DNA damage repair is complete.  Conceivably, modulating 
DDR downstream of ATM (e.g., p53, AP-1, NFB, Egr-1, SP1; reviewed in (52)) 
could further augment the beneficial effects of PQ with CDK4/6 inhibitors.  
D.  Summary: Contributions to HSPC and IR biology 
The present work has focused on a novel method of radioprotection 
through manipulation of the tissue-specific requirements for cellular proliferation 
in hematopoiesis.  Not only have these studies contributed to scientific 
understanding of the molecular requirements for cellular proliferation in HSPC, 
but these data have revealed a clear clinical application for the use of PQ in 
humans.  With positive clinical outcomes, the strategies outlined here may be 
applied in the clinical setting within a few years. 
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